disopyramide has been researched along with Auricular Flutter in 40 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 9.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 9.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| "0 micrograms/kg, n = 8), a class III drug, on atrial flutter (AF) caused by reentry were compared with those of disopyramide (1." | 7.68 | Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenone. ( Inoue, H; Nozaki, A; Saihara, S; Sugimoto, T; Usui, M; Yamashita, T, 1991) |
| "A study of the efficacy of intravenous disopyramide in the conversion of supraventricular tachyarrhythmias to sinus rhythm was undertaken in a group of 23 patients with a variety of cardiological diagnoses." | 7.67 | The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias. ( Ikram, H; Stewart, DE, 1984) |
| "The efficacy of intravenous disopyramide was studied during 200 episodes of supraventricular and ventricular arrhythmias in 160 patients, mainly presenting with acute myocardial infarction or cardiac failure." | 7.66 | Efficacy of intravenous disopyramide in acute cardiac arrhythmias. ( De Backer, M; Kahn, RJ; Stoupel, E, 1981) |
| "A 59-year-old man presented with atrial flutter and a 2:1 atrioventricular response, which, after intravenous disopyramide, became 1:1." | 7.66 | Extreme tachycardia complicating the use of disopyramide in atrial flutter. ( Miller, HC; Robertson, CE, 1980) |
| "Disopyramide (Norpace) is a recently released antiarrhythmic agent with quinidine-like actions, but structurally unique." | 5.26 | Disopyramide (Norpace)-induced hypoglycemia. ( Brown, LK; Goldberg, IJ; Rayfield, EJ, 1980) |
| "Atrial flutter was initiated, at study, by right atrial pacing and electrograms from the right atrium and coronary sinus were observed for at least five minutes to ensure stable flutter in both atria." | 5.26 | Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination. ( Camm, J; Spurrell, R; Ward, D, 1980) |
| "Safety and efficacy of propafenone and disopyramide for long-term maintenance of sinus rhythm after electrical cardioversion was studied in 56 patients with chronic atrial fibrillation (median arrhythmia duration, 5 months)." | 5.08 | Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group. ( Crijns, HJ; Gosselink, AT; Lie, KI, 1996) |
| "Six patients with reproducible inducible atrial flutter randomly received, in double-blinded fashion, 77 mg of S(+)-disopyramide and R(-)-disopyramide over 20 min by intravenous infusion on two occasions separated by at least 24 h." | 5.06 | Antiarrhythmic activity and unbound concentrations of disopyramide enantiomers in patients. ( Boudoulas, H; Lima, JJ; Schaal, SF; Wenzke, SC, 1990) |
| "The efficacy of sotalol in treating acute atrial fibrillation and flutter after open heart surgery was compared with that of a digoxin/disopyramide combination." | 5.05 | Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. ( Campbell, TJ; Gavaghan, TP; Morgan, JJ, 1985) |
| " The atrial activation at the CT was determined during programmed stimulation with one extrastimulus at five pacing sites anteriorly to the CT in 10 patients with atrial flutter and 10 patients with atrial fibrillation before and after intravenous administration of 2 mg/kg disopyramide." | 3.70 | Transverse conduction capabilities of the crista terminalis in patients with atrial flutter and atrial fibrillation. ( Fischenbeck, C; Hagendorff, A; Jung, W; Lewalter, T; Lüderitz, B; Omran, H; Schmidt, H; Schumacher, B; Wolpert, C, 1999) |
| "0 micrograms/kg, n = 8), a class III drug, on atrial flutter (AF) caused by reentry were compared with those of disopyramide (1." | 3.68 | Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenone. ( Inoue, H; Nozaki, A; Saihara, S; Sugimoto, T; Usui, M; Yamashita, T, 1991) |
| " To determine the exact role played by these two electrophysiologic effects in the termination of reentry, the effects of disopyramide, flecainide, propafenone and E-4031, a new class III drug, were examined in a canine model of atrial flutter (cycle length 120 +/- 4 to 131 +/- 3 ms) caused by reentry." | 3.68 | Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap. ( Inoue, H; Nozaki, A; Sugimoto, T; Yamashita, T, 1991) |
| "A study of the efficacy of intravenous disopyramide in the conversion of supraventricular tachyarrhythmias to sinus rhythm was undertaken in a group of 23 patients with a variety of cardiological diagnoses." | 3.67 | The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias. ( Ikram, H; Stewart, DE, 1984) |
| "The efficacy of intravenous disopyramide was studied during 200 episodes of supraventricular and ventricular arrhythmias in 160 patients, mainly presenting with acute myocardial infarction or cardiac failure." | 3.66 | Efficacy of intravenous disopyramide in acute cardiac arrhythmias. ( De Backer, M; Kahn, RJ; Stoupel, E, 1981) |
| ", verapamil, disopyramide, and procainamide, on paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (Af) and atrial flutter (AF) were evaluated electrophysiologically." | 3.66 | Electrophysiologic evaluation of antiarrhythmic drugs on supraventricular tachyarrhythmias. ( Hiejima, K; Satake, S; Suzuki, F; Takahashi, M, 1983) |
| "A 59-year-old man presented with atrial flutter and a 2:1 atrioventricular response, which, after intravenous disopyramide, became 1:1." | 3.66 | Extreme tachycardia complicating the use of disopyramide in atrial flutter. ( Miller, HC; Robertson, CE, 1980) |
| "Disopyramide phosphate was administered intravenously to 57 patients with 60 episodes of arrhythmia (21 supraventricular and 39 ventricular) as a 2 mg/kg bolus." | 3.65 | The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. ( Deano, DA; Ehsani, AI; Mautner, RK; Rosen, KM; Sherman, RH; Wu, D, 1977) |
| "Atrial flutter is most often arising from a macroreentry circuit in the right atrium or around scar tissue in case or previous cardiothoracic surgery." | 2.43 | [Atrial flutter and fibrillation]. ( Scharf, C, 2005) |
| "Disopyramide (Norpace) is a recently released antiarrhythmic agent with quinidine-like actions, but structurally unique." | 1.26 | Disopyramide (Norpace)-induced hypoglycemia. ( Brown, LK; Goldberg, IJ; Rayfield, EJ, 1980) |
| "Atrial flutter was initiated, at study, by right atrial pacing and electrograms from the right atrium and coronary sinus were observed for at least five minutes to ensure stable flutter in both atria." | 1.26 | Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination. ( Camm, J; Spurrell, R; Ward, D, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (65.00) | 18.7374 |
| 1990's | 13 (32.50) | 18.2507 |
| 2000's | 1 (2.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scharf, C | 1 |
| Theisen, K | 1 |
| De Backer, M | 1 |
| Stoupel, E | 1 |
| Kahn, RJ | 1 |
| Stewart, DE | 1 |
| Ikram, H | 1 |
| Chia, BL | 1 |
| Choo, MH | 1 |
| Tan, AT | 1 |
| Ee, B | 1 |
| Hiejima, K | 1 |
| Suzuki, F | 1 |
| Takahashi, M | 1 |
| Satake, S | 1 |
| Goldberg, IJ | 1 |
| Brown, LK | 1 |
| Rayfield, EJ | 1 |
| Beck, OA | 1 |
| Günther, R | 1 |
| Hochrein, H | 1 |
| Camm, J | 2 |
| Ward, D | 2 |
| Spurrell, R | 1 |
| Robertson, CE | 1 |
| Miller, HC | 1 |
| Boudonas, G | 1 |
| Lefkos, N | 1 |
| Efthymiadis, AP | 1 |
| Styliadis, IG | 1 |
| Tsapas, G | 1 |
| Manz, M | 1 |
| Lüderitz, B | 2 |
| Jordaens, L | 1 |
| Missault, L | 1 |
| Germonpré, E | 1 |
| Callens, B | 1 |
| Adang, L | 1 |
| Vandenbogaerde, J | 1 |
| Clement, DL | 1 |
| Ohga, N | 1 |
| Inoue, T | 2 |
| Doi, T | 1 |
| Yoshida, A | 1 |
| Yokoyama, M | 1 |
| Crijns, HJ | 1 |
| Gosselink, AT | 1 |
| Lie, KI | 1 |
| Brembilla-Perrot, B | 1 |
| Terrier de la Chaise, A | 1 |
| Jacquemin, L | 1 |
| Beurrier, D | 1 |
| Houplon, P | 1 |
| Louis, P | 1 |
| Danchin, N | 1 |
| Schumacher, B | 1 |
| Jung, W | 1 |
| Schmidt, H | 1 |
| Fischenbeck, C | 1 |
| Lewalter, T | 1 |
| Hagendorff, A | 1 |
| Omran, H | 1 |
| Wolpert, C | 1 |
| Donaldson, RM | 1 |
| Dreifus, LS | 1 |
| Perroni, GB | 1 |
| Briguglio, FS | 1 |
| Oddo, A | 1 |
| Trovato, G | 1 |
| Fox, K | 1 |
| Evans, T | 1 |
| Rowland, E | 1 |
| Krikler, D | 1 |
| Spurrell, RA | 1 |
| Deano, DA | 1 |
| Wu, D | 1 |
| Mautner, RK | 1 |
| Sherman, RH | 1 |
| Ehsani, AI | 1 |
| Rosen, KM | 1 |
| Fowler, NO | 1 |
| Dean, RR | 2 |
| Inoue, H | 3 |
| Yamashita, T | 3 |
| Usui, M | 2 |
| Nozaki, A | 3 |
| Saihara, S | 1 |
| Sugimoto, T | 3 |
| Lima, JJ | 1 |
| Wenzke, SC | 1 |
| Boudoulas, H | 1 |
| Schaal, SF | 1 |
| Grosu, AA | 1 |
| Shevchenko, NM | 1 |
| Kushakovskiĭ, MS | 1 |
| Grishkin, IuN | 1 |
| Della Bella, P | 3 |
| Marenzi, G | 3 |
| Doni, F | 3 |
| Tondo, C | 3 |
| Cipolla, C | 1 |
| Grazi, S | 3 |
| Rimondini, A | 2 |
| Salvioni, A | 2 |
| Guazzi, MD | 3 |
| Fujimoto, T | 1 |
| Ogawa, H | 1 |
| Miwa, S | 1 |
| Ohnishi, Y | 1 |
| Yoneda, N | 1 |
| Kaneda, S | 1 |
| Itoh, S | 1 |
| Fukuzaki, H | 1 |
| Lauri, G | 1 |
| Martin, A | 1 |
| Benbow, LJ | 1 |
| Leach, C | 1 |
| Bailey, RJ | 1 |
| Cipolla, CM | 1 |
| Gavaghan, TP | 2 |
| Feneley, MP | 1 |
| Campbell, TJ | 2 |
| Morgan, JJ | 2 |
| Lisin, N | 1 |
| Andriange, M | 1 |
| Vandenbosch, R | 1 |
| Carlier, J | 1 |
| Lin, TK | 1 |
| Chien, YW | 1 |
| Dutt, JE | 1 |
| Sause, HW | 1 |
| Yen, CH | 1 |
| Yonan, PK | 1 |
2 reviews available for disopyramide and Auricular Flutter
| Article | Year |
|---|---|
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia | 2005 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
10 trials available for disopyramide and Auricular Flutter
| Article | Year |
|---|---|
[Conversion of chronic atrial fibrillation or flutter with disopyramide and a verapamil-quinidine combination: a comparative study ].
Topics: Aged; Atrial Flutter; Disopyramide; Drug Combinations; Female; Humans; Male; Middle Aged; Pyridines; | 1982 |
Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Diltiazem; Disopyramide; Electrocardiogr | 1995 |
Delayed restoration of atrial function after conversion of atrial flutter by pacing or electrical cardioversion.
Topics: Adult; Aged; Aged, 80 and over; Atrial Flutter; Atrial Function; Blood Flow Velocity; Cardiac Output | 1993 |
Effects of class IA antiarrhythmic drugs on the reentrant circuit in common human atrial flutter.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Disopyramide; Elect | 1995 |
Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Disopyramide; Do | 1996 |
Clinical studies of Norpace. Summarizing remarks.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; At | 1975 |
Antiarrhythmic activity and unbound concentrations of disopyramide enantiomers in patients.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Dialysis; Disopyramide; Female; Humans; Male; Orosomucoid; S | 1990 |
Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter (interim report).
Topics: Aged; Amiodarone; Atrial Fibrillation; Atrial Flutter; Benzofurans; Disopyramide; Female; Humans; Ma | 1986 |
Facilitating influence of disopyramide on atrial flutter termination by overdrive pacing.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atrial Flutter; Atrioventricular Node; Cardiac Pacing | 1988 |
Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial.
Topics: Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Clinical Trials as Topic; Digoxin; Diso | 1985 |
28 other studies available for disopyramide and Auricular Flutter
| Article | Year |
|---|---|
[Pharmacotherapy of paroxysmal tachycardia].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Disopyramide | 1983 |
Efficacy of intravenous disopyramide in acute cardiac arrhythmias.
Topics: Acute Disease; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; C | 1981 |
The use of intravenous disopyramide for the conversion of supraventricular tachyarrhythmias.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Disopyramide; Dr | 1984 |
Atrial flutter in Wolff-Parkinson-White syndrome responding to intravenous disopyramide.
Topics: Aged; Atrial Flutter; Disopyramide; Electrocardiography; Female; Humans; Infusions, Parenteral; Wolf | 1984 |
Electrophysiologic evaluation of antiarrhythmic drugs on supraventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atrioventricular Node; Disopyramide; El | 1983 |
Disopyramide (Norpace)-induced hypoglycemia.
Topics: Aged; Alanine; Atrial Flutter; Disopyramide; Female; Glucagon; Gluconeogenesis; Glucose Tolerance Te | 1980 |
Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination.
Topics: Adult; Atrial Flutter; Cardiac Pacing, Artificial; Disopyramide; Electrocardiography; Female; Humans | 1980 |
Extreme tachycardia complicating the use of disopyramide in atrial flutter.
Topics: Atrial Flutter; Disopyramide; Humans; Male; Middle Aged; Pyridines; Tachycardia | 1980 |
[Can 1/1 atrial flutter be foreseen by class I anti-arrhythmics?].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Electrocardiography; Female; Flecainide; | 1997 |
Transverse conduction capabilities of the crista terminalis in patients with atrial flutter and atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Disop | 1999 |
The treatment of supraventricular arrhythmias.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhyt | 1979 |
Clinical studies of Norpace (Part X).
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes | 1975 |
[Data on disopyridamide therapy of some arrhythmias].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes, Premature; Disopyramid | 1977 |
'Bradycardia-tachycardia' syndrome 8 yr after correction of Fallot's tetralogy.
Topics: Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Bradycardia; Child; Child, Preschool; Death, Sudde | 1979 |
The effect of intravenous disopyramide phosphate on recurrent paroxysmal tachycardias.
Topics: Atrial Fibrillation; Atrial Flutter; Blood Pressure; Disopyramide; Electrocardiography; Humans; Infu | 1979 |
The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Disopy | 1977 |
The pharmacology of Norpace.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrioven | 1975 |
Effects of pentisomide and E-4031 on canine atrial flutter due to reentry: a comparative study with disopyramide and propafenone.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Dogs; Electrocardiography; Electrophy | 1991 |
Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Dogs; Flecainide; Heart Conduction Sy | 1991 |
Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Disopyramide; Dogs; Ele | 1991 |
[The potentials for curing atrial flutter by the combined use of transesophageal electrical stimulation and anti-arrhythmia preparations].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Pacing, Artificial; Chronic Disease; Co | 1990 |
[Dissociated (dissimilar) atrial rhythms after administration of ritmilen].
Topics: Atrial Fibrillation; Atrial Flutter; Disopyramide; Electrocardiography; Female; Humans; Middle Aged | 1990 |
[Efficacy of disopyramide in the treatment of atrial flutter with overdrive pacing].
Topics: Aged; Atrial Flutter; Cardiac Pacing, Artificial; Chronic Disease; Disopyramide; Electrocardiography | 1989 |
The effects of class IA antiarrhythmic drug on the common type of atrial flutter in combination with pacing therapy.
Topics: Adult; Aged; Atrial Flutter; Cardiac Pacing, Artificial; Combined Modality Therapy; Disopyramide; El | 1989 |
Effects of disopyramide on cycle length, effective refractory period and excitable gap of atrial flutter, and relation to arrhythmia termination by overdrive pacing.
Topics: Aged; Atrial Flutter; Cardiac Pacing, Artificial; Disopyramide; Electrocardiography; Female; Humans; | 1989 |
Atrial tachyarrhythmias after cardiac surgery: results of disopyramide therapy.
Topics: Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Digoxin; Disopyramide; Drug Therap | 1985 |
[Treatment of disturbances of cardiac rhythm using intravenous disopyramide].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Brad | 1974 |
Quantum statistical calculation for the correlation of biological activity and chemical structure. 3. Diisopyramide phosphate and related compounds as antiarrhythmic agents.
Topics: Aconitum; Animals; Anti-Arrhythmia Agents; Atrial Flutter; Disopyramide; Dogs; Models, Biological; M | 1974 |